icon-folder.gif   Conference Reports for NATAP  
 
  51th ICAAC
Chicago, IL
September 17-20, 2011
Back grey_arrow_rt.gif
 
 
 
Rilpivirine (TMC278) tolerability over the first 12 weeks of treatmentin the Phase III ECHO and THRIVE studies
 
 
  Reported by Jules Levin
51st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA, September 17-20 2011
 
Bruce Rashbaum,1 Pierre-Marie Girard,2 Anita Rachlis,3 Diana Pedral-Sampaio,4 Aimee Wilkin,5 Simon Vanveggel,6 Katia Boven7 1Capital Medical Associates, Washington, DC, USA; 2H˘pital Saint Antoine, Paris, France; 3Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada; 4Federal University of Bahia, Brazil;5Wake Forest University Health Sciences, Winston-Salem, NC, USA; 6Tibotec BVBA, Beerse, Belgium; 7Tibotec Inc. Titusville, NJ, USA

ICAAC1.gif

ICAAC2.gif

ICAAC3.gif

ICAAC4.gif

ICAAC5.gif

ICAAC6.gif

ICAAC7.gif

ICAAC8.gif

ICAAC9.gif

ICAAC10.gif

ICAAC11.gif